Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 3/20 | 0.35 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.33 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.33 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.32 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24542838 | 0.78 | MMP3 (0.33) | PTGS1KCNH2 | |
| SCHEMBL24543237 | 0.77 | CTSS (0.33) | — | |
| SCHEMBL22567170 | 0.76 | TGFBR1 (0.37) | ECE1BBOX1NAALAD2MME | |
| SCHEMBL24543232 | 0.74 | CTSS (0.36) | — | |
| SCHEMBL24543149 | 0.74 | SPHK1 (0.36) | PTGS1KCNH2 | |
| SCHEMBL13428229 | 0.69 | HDAC2 (0.32) | — | |
| SCHEMBL29954080 | 0.67 | ECE1 (0.40) | ECE1BBOX1 | |
| SCHEMBL13599664 | 0.67 | MAPT (0.40) | MAPT | |
| SCHEMBL24729188 | 0.67 | MAPT (0.40) | MAPT | |
| SCHEMBL8369782 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194939-A1 | Novel compounds and methods of use treating fructose-related disorders or diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194939-A1 | Novel compounds and methods of use treating fructose-related disorders or diseases | GCK, KHK, HK1 | ECE1 1476/4885BBOX1 1072/4885NAALAD2 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.